<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">851</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2021-2-30-31</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A review of tender purchases of L01 group – antineoplastic agents</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kalinina</surname><given-names>Nadezhda</given-names></name><bio></bio><email>-</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">RM Analytics</aff><pub-date date-type="epub" iso-8601-date="2021-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2021</year></pub-date><issue>2</issue><fpage>30</fpage><lpage>31</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-17"><day>17</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2021,</copyright-statement><copyright-year>2021</copyright-year></permissions><abstract>It is clear now that 2021 will be as challenging as the previous year. The pandemic continues, the economic situation has a negative effect on all markets as before, including the pharmaceutical one. All participants in the pharmaceutical market are undertaking their best efforts to maintain operating supply chains and to ensure uninterrupted provision of population with the necessary drugs. Concurrently, the public procurement situation will directly depend on the morbidity rate in the population.</abstract><kwd-group xml:lang="en"><kwd>public procurement</kwd><kwd>FZ-44</kwd><kwd>FZ-223</kwd><kwd>pharm market</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>госзакупки</kwd><kwd>ФЗ-44</kwd><kwd>ФЗ-223</kwd><kwd>фармрынок</kwd></kwd-group></article-meta></front><body></body><back/></article>
